The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

Medullary thyroid carcinoma (MTC) is a rare malignancy originating from the calcitonin-
secreting parafollicular thyroid C cells. Approximately 75% of cases are sporadic …

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN
Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid …

Pazopanib is a relatively new compound to be introduced into the chemotherapy field. It is
thought to have decent anti-angiogenic properties, which gives an additional hope for the …

Since the discovery of bisphosphonate‐related osteonecrosis of the jaw, there has been
increasing evidence in recent years of osteonecrosis induced by drugs other than …

Cancer is a major threat to human life around the globe, and the discovery of novel
biomolecules continue to be an urgent therapeutic need that is still unmet. Precision …

Introduction: Acute myelogenous leukemia (AML) is a genetically heterogeneous disease.
Yet current therapy has changed little over the decades and includes the nucleoside analog …

Medullary thyroid cancer (MTC) is an aggressive form of thyroid cancer that occurs in both
heritable and sporadic forms. Discovery that mutations in the rearranged during transfection …

The number of individuals who succumb to thyroid cancer has been increasing and those
who are refractory to standard care have limited effective therapeutic options, highlighting …

The incidence of thyroid carcinoma is rapidly increasing. Although generally associated with
good prognosis, a fraction of thyroid tumors are not cured by standard therapy and progress …